Sanger sequencing versus INNO-LiPA® HBV PreCore assay for routine detection of precore and basal core promoter mutations in hepatitis virus B chronically infected patients

We compared the Sanger sequencing and the commercial INNO-LiPA® HBV assay for the routine detection of precore (PC) and basal core promoter (BCP) mutations of hepatitis B virus in chronically infected patients. The overall agreement rate between assays was 94.2% and 98.8% for the detection of PC and...

Full description

Saved in:
Bibliographic Details
Published in:Diagnostic microbiology and infectious disease 2018-04, Vol.90 (4), p.277-279
Main Authors: Alidjinou, E.K., Bocket, L., Pigot, V., Lambert, V., Hallaert, C., Canva, V., Hober, D.
Format: Article
Language:English
Subjects:
Basal core promoter
Hepatitis B virus
INNO-LiPA
Mutations
Precore
Sanger sequencing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We compared the Sanger sequencing and the commercial INNO-LiPA® HBV assay for the routine detection of precore (PC) and basal core promoter (BCP) mutations of hepatitis B virus in chronically infected patients. The overall agreement rate between assays was 94.2% and 98.8% for the detection of PC and BCP mutations, respectively. •We compared Sanger sequencing and INNO-LiPA® HBV PreCore assay.•A very good agreement was observed between both methods.•INNO-LiPA assay was a little faster, while reagent cost was lower, for sequencing.•The sequencing can allow the detection of additional mutations.
ISSN:0732-8893
1879-0070
DOI:10.1016/j.diagmicrobio.2017.12.006